Quest Diagnostics downgraded at BofA/Merrill As previously reported, BofA/Merrill downgraded Quest Diagnostics to Underperform from Buy. The firm downgraded shares due to a weak growth outlook, deal strategy changes, and impact from cost cutting program. Price target lowered to $55 from $64.
News For DGX From The Last 14 Days
Check below for free stories on DGX the last two weeks.